Despite the acknowledged challenges in eliciting effective tumor immunity, there are reports suggesting that tumor cells may exploit iDCs to promote tumor progression, influenced by tumor-derived soluble factors such as vascular endothelial growth factor (VEGF) [70]. The gene discussed is VEGFA; the disease is neoplasm.